Access cutting-edge non-alcoholic fatty liver disease treatment through this clinical trial at a research site in Las Vegas. Study-provided care at no cost to qualified participants.
Access non-alcoholic fatty liver disease specialists in Las Vegas at no cost
This study follows strict safety protocols and ethical guidelines
All study-related non-alcoholic fatty liver disease treatment provided free
The design of the Phase 2 clinical trial includes the following elements: * Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in approximately 40 patients in the U.S. * Patients will be randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks. * The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2)
Sponsor: MediciNova
Check if you qualify for this non-alcoholic fatty liver disease clinical trial in Las Vegas, NV
If you're searching for non-alcoholic fatty liver disease treatment options in Las Vegas, NV, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Las Vegas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-alcoholic fatty liver disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.